Inflammatory Pathways in Coronary Artery Disease: Which Ones to Target for Secondary Prevention?

Area of Science:

• Cardiovascular Medicine
• Immunology
• Pharmacology

Background:

• Coronary artery disease (CAD) involves atherosclerotic plaque buildup, leading to adverse cardiovascular events.
• Secondary prevention strategies aim to manage existing plaques and halt disease progression.
• Inflammation is recognized as a critical independent risk factor accelerating CAD progression.

Purpose of the Study:

• To review the role of inflammatory pathways in plaque rupture and erosion, key mechanisms of CAD events.
• To analyze lessons from clinical trials targeting inflammatory pathways for CAD secondary prevention.
• To advocate for assessing inflammation in established plaques to guide future therapeutic development.

Main Methods:

• Review of scientific literature and clinical trial data on inflammatory pathways in CAD.
• Analysis of therapeutic strategies targeting inflammatory cytokines and signaling pathways.
• Evaluation of pre-clinical models' utility in understanding inflammation in established plaques.

Main Results:

• Numerous clinical trials targeting inflammation have yielded limited success, with only colchicine approved for CAD.
• The complex, multifaceted roles of inflammatory pathways contribute to the challenges in therapeutic development.
• Pre-clinical models are effective for early disease but offer limited insight into inflammation within established plaques.

Conclusions:

• Targeting inflammation holds therapeutic potential for CAD secondary prevention, but requires a nuanced approach.
• Understanding the inflammatory network in established plaques is crucial before designing targeted therapies.
• Future research should focus on better assessment of inflammation in established plaques to improve treatment efficacy.